Mariana Sofia Silva Carvalho

Dr. Mariana Sofia Silva Carvalho

Toxicology, Instituto Universitário de Ciências da Saúde, Gandra, Portugal
orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 July 2025 in Journal of Xenobiotics
Verified
Journal Article
Open access
PDF file
Ana Filipa SobralAna Filipa Sobral
Ana Filipa Sobral
Andrea Teixeira da CunhaAndrea Teixeira da Cunha
Andrea Teixeira da Cunha
ICInês Costa
Inês Costa
Mariana Sofia Silva CarvalhoMariana Sofia Silva Carvalho
Mariana Sofia Silva Carvalho
RSRenata Silva
Renata Silva
Daniel José BarbosaDaniel José Barbosa
Daniel José Barbosa
Environmental xenobiotics, including heavy metals, endocrine-disrupting chemicals (EDCs), pesticides, air pollutants, nano- and microplastics, mycotoxins, and phycotoxins, are widespread compounds that pose significant risks to human health. These substances, originating from industrial and agricultural activities, vehicle emissions, and household products, disrupt cellular homeostasis and contribute to a range of diseases, including cancer and neurodegenerative diseases, among others. Emerging evidence indicates that epigenetic alterations, such as abnormal deoxyribonucleic acid (DNA) methylation, aberrant histone modifications, and altered expression of non-coding ribonucleic acids (ncRNAs), may play a central role in mediating the toxic effects of environmental xenobiotics. Furthermore, exposure to these compounds during critical periods, such as embryogenesis and early postnatal stages, can induce long-lasting epigenetic alterations that increase susceptibility to diseases later in life. Moreover, modifications to the gamete epigenome can potentially lead to effects that persist across generations (transgenerational effects). Although these modifications represent significant health risks, many epigenetic alterations may be reversible through the removal of the xenobiotic trigger, offering potential for therapeutic intervention. This review explores the relationship between environmental xenobiotics and alterations in epigenetic signatures, focusing on how these changes impact human health, including their potential for transgenerational inheritance and their potential reversibility.

26 September 2025 in Basic & Clinical Pharmacology & Toxicology
Verified
Journal Article
Open access
Mariana Sofia Silva CarvalhoMariana Sofia Silva Carvalho
Mariana Sofia Silva Carvalho
DBDaniel José Barbosa
Daniel José Barbosa
DSDiana Dias da Silva
Diana Dias da Silva
Ricardo Jorge Dinis-OliveiraRicardo Jorge Dinis-Oliveira
Ricardo Jorge Dinis-Oliveira
Lisdexamfetamine (LDX), a prodrug of d ‐amphetamine, is widely used in the pharmacological treatment of neuropsychiatric disorders such as attention‐deficit/hyperactivity disorder (ADHD) and binge eating disorder (BED). Chemically, it consists of the amino acid lysine linked to d ‐amphetamine. Its enzymatic conversion to d ‐amphetamine sets the stage for a prolonged and controlled release, influencing its clinical profile and differentiating it from other stimulant medications. As a central nervous system stimulant, LDX primarily acts by increasing the release of neurotransmitters, particularly dopamine and noradrenaline, in the brain. Clinically, this enhanced availability of neurotransmitters is believed to contribute to improvements in attention, focus and impulse control in individuals with ADHD. The side effects of LDX include insomnia, decreased appetite, weight loss and xerostomia. This work reviews the pharmacological mechanisms, clinical applications and forensic considerations associated with its use. It is expected that clinicians, researchers and policymakers have a comprehensive understanding of the pharmacological and toxicological aspects of LDX.